Cargando…

P53 and Beta-Catenin Activity during Estrogen treatment of Osteoblasts

BACKGROUND: This study was undertaken to examine the relationship between the tumor suppressor gene p53 and the nuclear signaling protein beta-catenin during bone differentiation. Cross talk between p53 and beta-catenin pathways has been demonstrated and is important during tumorigenesis and DNA dam...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandar, Nalini, Saluja, Rasleen, Lamar, Peter C, Kolman, Kevin, Prozialeck, Walter C
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1192811/
https://www.ncbi.nlm.nih.gov/pubmed/16053526
http://dx.doi.org/10.1186/1475-2867-5-24
_version_ 1782124819194576896
author Chandar, Nalini
Saluja, Rasleen
Lamar, Peter C
Kolman, Kevin
Prozialeck, Walter C
author_facet Chandar, Nalini
Saluja, Rasleen
Lamar, Peter C
Kolman, Kevin
Prozialeck, Walter C
author_sort Chandar, Nalini
collection PubMed
description BACKGROUND: This study was undertaken to examine the relationship between the tumor suppressor gene p53 and the nuclear signaling protein beta-catenin during bone differentiation. Cross talk between p53 and beta-catenin pathways has been demonstrated and is important during tumorigenesis and DNA damage, where deregulation of beta catenin activates p53. In this study, we used estrogen treatment of osteoblasts as a paradigm to study the relationship between the two proteins during osteoblast differentiation. RESULTS: We exposed osteoblast-like ROS17/2.8 cells to 17-beta estradiol (E2), in a short term assay, and studied the cellular distribution and expression of beta-catenin. We found beta-catenin to be up regulated several fold following E2 treatment. Levels of p53 and its functional activity mirrored the quantitative changes seen in beta-catenin. Alkaline phosphatase, an early marker of osteoblast differentiation, was increased in a manner similar to beta-catenin and p53. In order to determine if there was a direct relationship between alkaline phosphatase expression and beta-catenin, we used two different approaches. In the first approach, treatment with LiCl, which is known to activate beta-catenin, caused a several fold increase in alkaline phosphatase activity. In the second approach, transient transfection of wild type beta-catenin into osteoblasts increased alkaline phosphatase activity two fold over basal levels, showing that beta catenin expression can directly affect alkaline phosphatase expression. However increase in beta catenin activity was not associated with an increase in its signaling activity through TCF/LEF mediated transcription. Immunofluorescence analyses of p53 and beta-catenin localization showed that E2 first caused an increase in cytosolic beta-catenin followed by the accumulation of beta-catenin in the nucleus. Nuclear p53 localization was detected in several cells. Expression of p53 was accompanied by distribution of beta-catenin to the cytoplasm and cell borders. A sub population of cells staining strongly for both proteins appeared to be apoptotic. CONCLUSION: These results suggest that interactions between p53 and beta-catenin signaling pathways may play a key role in osteoblast differentiation and maintenance of tissue homeostasis.
format Text
id pubmed-1192811
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-11928112005-08-27 P53 and Beta-Catenin Activity during Estrogen treatment of Osteoblasts Chandar, Nalini Saluja, Rasleen Lamar, Peter C Kolman, Kevin Prozialeck, Walter C Cancer Cell Int Primary Research BACKGROUND: This study was undertaken to examine the relationship between the tumor suppressor gene p53 and the nuclear signaling protein beta-catenin during bone differentiation. Cross talk between p53 and beta-catenin pathways has been demonstrated and is important during tumorigenesis and DNA damage, where deregulation of beta catenin activates p53. In this study, we used estrogen treatment of osteoblasts as a paradigm to study the relationship between the two proteins during osteoblast differentiation. RESULTS: We exposed osteoblast-like ROS17/2.8 cells to 17-beta estradiol (E2), in a short term assay, and studied the cellular distribution and expression of beta-catenin. We found beta-catenin to be up regulated several fold following E2 treatment. Levels of p53 and its functional activity mirrored the quantitative changes seen in beta-catenin. Alkaline phosphatase, an early marker of osteoblast differentiation, was increased in a manner similar to beta-catenin and p53. In order to determine if there was a direct relationship between alkaline phosphatase expression and beta-catenin, we used two different approaches. In the first approach, treatment with LiCl, which is known to activate beta-catenin, caused a several fold increase in alkaline phosphatase activity. In the second approach, transient transfection of wild type beta-catenin into osteoblasts increased alkaline phosphatase activity two fold over basal levels, showing that beta catenin expression can directly affect alkaline phosphatase expression. However increase in beta catenin activity was not associated with an increase in its signaling activity through TCF/LEF mediated transcription. Immunofluorescence analyses of p53 and beta-catenin localization showed that E2 first caused an increase in cytosolic beta-catenin followed by the accumulation of beta-catenin in the nucleus. Nuclear p53 localization was detected in several cells. Expression of p53 was accompanied by distribution of beta-catenin to the cytoplasm and cell borders. A sub population of cells staining strongly for both proteins appeared to be apoptotic. CONCLUSION: These results suggest that interactions between p53 and beta-catenin signaling pathways may play a key role in osteoblast differentiation and maintenance of tissue homeostasis. BioMed Central 2005-07-29 /pmc/articles/PMC1192811/ /pubmed/16053526 http://dx.doi.org/10.1186/1475-2867-5-24 Text en Copyright © 2005 Chandar et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Primary Research
Chandar, Nalini
Saluja, Rasleen
Lamar, Peter C
Kolman, Kevin
Prozialeck, Walter C
P53 and Beta-Catenin Activity during Estrogen treatment of Osteoblasts
title P53 and Beta-Catenin Activity during Estrogen treatment of Osteoblasts
title_full P53 and Beta-Catenin Activity during Estrogen treatment of Osteoblasts
title_fullStr P53 and Beta-Catenin Activity during Estrogen treatment of Osteoblasts
title_full_unstemmed P53 and Beta-Catenin Activity during Estrogen treatment of Osteoblasts
title_short P53 and Beta-Catenin Activity during Estrogen treatment of Osteoblasts
title_sort p53 and beta-catenin activity during estrogen treatment of osteoblasts
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1192811/
https://www.ncbi.nlm.nih.gov/pubmed/16053526
http://dx.doi.org/10.1186/1475-2867-5-24
work_keys_str_mv AT chandarnalini p53andbetacateninactivityduringestrogentreatmentofosteoblasts
AT salujarasleen p53andbetacateninactivityduringestrogentreatmentofosteoblasts
AT lamarpeterc p53andbetacateninactivityduringestrogentreatmentofosteoblasts
AT kolmankevin p53andbetacateninactivityduringestrogentreatmentofosteoblasts
AT prozialeckwalterc p53andbetacateninactivityduringestrogentreatmentofosteoblasts